Overall, the findings demonstrated that SPP1/HMOX1 were associated with poor overall survival in glioma patients, indicating their potential as clinical prognostic and therapeutic targets of oncolytic virus treatment. The gene discussed is SPP1; the disease is central nervous system cancer.